This year’s American Association for Cancer Research meeting featured plenary talks by two NCI scientists, Steven Rosenberg, M.D., and Louis Staudt, M.D., Ph.D., that highlighted the challenges in developing varied and potentially synergistic treatments for aggressive forms of cancer. Each researcher has been focusing primarily on a particularly difficult to treat cancer (melanoma and lymphoma, respectively) for many decades, and their presentations highlight the diligence and tenacity needed to come to a better understanding of the cancer process and to find effective agents to target the diseases they study.
NCI is launching a new clinical trials research network intended to improve treatment for the more than 1.6 million Americans diagnosed with cancer each year. The new system, NCI’s National Clinical Trials Network (NCTN), will facilitate the rapid initiation and completion of cancer clinical trials at over 3,000 clinical trials sites.
A pilot trial to assess whether assigning treatment based on specific gene mutations can provide benefit to patients with metastatic solid tumors is being launched this month by the NCI. The Molecular Profiling based Assignment of Cancer Therapeutics, or M-PACT, trial is one of the first to use a randomized trial design to assess if assigning treatment based on genetic screening can improve the rate and duration of response in patients with advanced solid tumors.
Introduction of the UroNav was the result of nearly a decade’s research and development, principally conducted at NCI. Resembling a stylized computer workstation on wheels, the system electronically fuses together pictures from magnetic resonance imaging and ultrasound to create a detailed, three-dimensional view of the prostate, which physicians can then use to guide precision biopsies.
To address concerns of colorectal cancer recurring after initial treatment, NCI, in collaboration with SWOG, one of NCI’s cooperative groups, recently announced a phase III trial that looks at whether someone who has been treated for colon cancer in the past can lower his or her risk of having a second primary colorectal cancer or an adenoma by regularly taking one or both of the study drugs, eflornithine and sulindac.
The Annual Report to the Nation on the Status of Cancer, covering the period 1975–2010, showed death rates for lung cancer, which accounts for more than one in four cancer deaths, dropping at a faster pace than in previous years.
- Study in mice shows that an aggressive type of breast cancer is linked to an inflammatory proteinApril 14, 2014
- An Open Letter to the Cancer Community Regarding Community Clinical TrialsApril 11, 2014
- NCI intramural research highlighted at 2014 AACR meetingApril 7, 2014
- Statement on Forthcoming Changes in NCI's Clinical Trials ProgramsApril 4, 2014
The Annual Report to the Nation on the Status of Cancer, 1975–2009, shows that overall cancer death rates continued to decline in the U.S. among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites.
- New gene variant increases the risk of colorectal cancerApril 18, 2014
- Chronic inflammation linked to high-grade prostate cancerApril 18, 2014
- Study identifies a likely key driver of colorectal cancerApril 17, 2014
- Gene panel screens dozens of genes for cancer mutationsApril 15, 2014